Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Diaphragm plasticity in aging and disease: therapies for muscle weakness go from strength to strength
Greising, Sarah M. , Ottenheijm, Coen A. C. , O’Halloran, Ken D. , Barreiro, Esther

Mayo Clinic

Journal of Applied Physiology | April 19, 2018 | Volume: 125 | Issue: 2 | Pages: 243-253

10.1152/japplphysiol.01059.2017 | PMID 29672230 Get It

The diaphragm is the main inspiratory muscle and is required to be highly active throughout the life span. The diaphragm muscle must be able to produce and sustain various behaviors that range from ventilatory to nonventilatory such as those required for airway maintenance and clearance. Throughout the life span various circumstances and conditions may affect the ability of the diaphragm muscle to generate requisite forces, and in turn the diaphragm muscle may undergo significant weakness and dysfunction. For example, hypoxic stress, critical illness, cancer cachexia, chronic obstructive pulmonary disorder, and age-related sarcopenia all represent conditions in which significant diaphragm muscle dysfunction exits. This perspective review article presents several interesting topics involving diaphragm plasticity in aging and disease that were presented at the International Union of Physiological Sciences Conference in 2017. This review seeks to maximize the broad and collective research impact on diaphragm muscle dysfunction in the search for transformative treatment approaches to improve the diaphragm muscle health during aging and disease.
Upregulation of the Oncogenic Helix-Loop-Helix Protein ID2 in Ewing Sarcoma
Park, Hye‐Rim , Jung, Woon Won, Santini-Araujo, Eduard, Kalil, Ricardo K. , Bacchini, Patrizia, Bertoni, Franco, Unni, K. Krishnan, Park, Yong-Koo , Kim, Hyun Sook , Santini‐Araujo, Eduardo

Mayo Clinic

Tumori Journal | April 16, 2018 | Volume: 92 | Issue: 3 | Pages: 236-240

10.1177/030089160609200309 Get It

Aims and background Id helix-loop-helix proteins function as regulators of cell growth and differentiation. However, they can induce malignant transformation when overexpressed. The EWS/ETS chimeric proteins in Ewing sarcoma act as aberrant transcription factors leading to tumorigenic processes. An enhanced expression of the Id2 gene in Ewing sarcoma cells was previously shown by gene array techniques. We investigated the expression of Id2 at the protein and gene level in Ewing sarcoma. Methods We evaluated the expression of Id2 protein using immunohistochemistry in formalin-fixed, paraffin-embedded specimens from a total of 71 cases of Ewing sarcoma. Additionally, a Ewing sarcoma cell line was examined by real-time quantitative PCR. Results Id2 expression was observed in 65 cases (91.5%) of the 71 total cases examined and a high level of Id2 expression was observed in 45 of these cases (63.8%). In tumor cells, Id2 proteins displayed cytoplasmic as well as nuclear localization. The amplification of the Id2 gene was not noted in a Ewing sarcoma cell line using real-time quantitative PCR. The crossing points of Id2 in the Ewing sarcoma cell line, control fibroblast, and osteosarcoma cell line were 18.54 ± 0.16, 18.25, and 18.34, respectively. Conclusions Our data support a role for increased Id2 protein expression in Ewing sarcoma. However, this overexpression of the Id2 protein could not be confirmed by a corresponding change at the gene level in a Ewing sarcoma cell line.
Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer
West, Diana C., Kocherginsky, Masha , Tonsing-Carter, Eva , Dolcen, Deniz Nesli , Hosfield, David J., Lastra, Ricardo R. , Sinnwell, Jason P. , Bowie, Kathleen R. , Skor, Maxwell N., Pierce, Charles F., Styke, Sarah C., Kim, Caroline R. , Wet, Larischa de, Wang, Liewei , Győrffy, Balázs , Conzen, Suzanne D. , Thompson, Kevin J. , Greene, Geoffrey L , Sinnwell, Jason P , Harkless, Ryan V. , Boughey, Judy C. , Goetz, Matthew P. , Kalari, Krishna R. , Fleming, Gini F. , Győrffy, Balázs

Mayo Clinic

Clinical Cancer Research | April 10, 2018 | Volume: 24 | Issue: 14 | Pages: 3433-3446

10.1158/1078-0432.ccr-17-2793 | PMID 29636357 Get It

Abstract Purpose: Although high glucocorticoid receptor (GR) expression in early-stage estrogen receptor (ER)-negative breast cancer is associated with shortened relapse-free survival (RFS), how associated GR transcriptional activity contributes to aggressive breast cancer behavior is not well understood. Using potent GR antagonists and primary tumor gene expression data, we sought to identify a tumor-relevant gene signature based on GR activity that would be more predictive than GR expression alone. Experimental Design: Global gene expression and GR ChIP-sequencing were performed to identify GR-regulated genes inhibited by two chemically distinct GR antagonists, mifepristone and CORT108297. Differentially expressed genes from MDA-MB-231 cells were cross-evaluated with significantly expressed genes in GR-high versus GR-low ER-negative primary breast cancers. The resulting subset of GR-targeted genes was analyzed in two independent ER-negative breast cancer cohorts to derive and then validate the GR activity signature (GRsig). Results: Gene expression pathway analysis of glucocorticoid-regulated genes (inhibited by GR antagonism) revealed cell survival and invasion functions. GR ChIP-seq analysis demonstrated that GR antagonists decreased GR chromatin association for a subset of genes. A GRsig that comprised n = 74 GR activation-associated genes (also reversed by GR antagonists) was derived from an adjuvant chemotherapy-treated Discovery cohort and found to predict probability of relapse in a separate Validation cohort (HR = 1.9; P = 0.012). Conclusions: The GRsig discovered herein identifies high-risk ER-negative/GR-positive breast cancers most likely to relapse despite administration of adjuvant chemotherapy. Because GR antagonism can reverse expression of these genes, we propose that addition of a GR antagonist to chemotherapy may improve outcome for these high-risk patients. Clin Cancer Res; 24(14); 3433–46. ©2018 AACR.
Increased Chromogranin A–Positive Hormone-Negative Cells in Chronic Pancreatitis
Moin, Abu Saleh Md , Cory, Megan , Choi, Jennifer, Ong, Allison, Dhawan, Sangeeta , Butler, Peter C. , Rizza, Robert A., Butler, Alexandra E. , Ong, Allison, Dhawan, Sangeeta , Dry, Sarah

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 6, 2018 | Volume: 103 | Issue: 6 | Pages: 2126-2135

10.1210/jc.2017-01562 | PMID 29659906 Get It

AbstractContextChronic pancreatitis (CP) is characterized by inflammation, fibrosis, and a loss of pancreatic acinar cells, which can result in exocrine and eventually endocrine deficiency. Pancreatitis has been reported to induce formation of new endocrine cells (neogenesis) in mice. Our recent data have implicated chromogranin A–positive hormone-negative (CPHN) cells as potential evidence of neogenesis in humans.ObjectiveWe sought to establish if CPHN cells were more abundant in CP in humans.Design, Setting, and ParticipantsWe investigated the frequency and distribution of CPHN cells and the expression of the chemokine C-X-C motif ligand 10 (CXCL10) and its receptor chemokine C-X-C motif receptor 3 in pancreas of nondiabetic subjects with CP.ResultsCPHN cell frequency in islets was increased sevenfold in CP [2.1% ± 0.67% vs 0.35% ± 0.09% CPHN cells in islets, CP vs nonpancreatitis (NP), P < 0.01], as were the CPHN cells found as scattered cells in the exocrine areas (17.4 ± 2.9 vs 4.2 ± 0.6, CP vs NP, P < 0.001). Polyhormonal endocrine cells were also increased in CP (2.7 ± 1.2 vs 0.1 ± 0.04, CP vs NP, % of polyhormonal cells of total endocrine cells, P < 0.01), as was expression of CXCL10 in α and β cells.ConclusionThere is increased islet endogenous expression of the inflammation marker CXCL10 in islets in the setting of nondiabetic CP and an increase in polyhormonal (insulin-glucagon expressing) cells. The increase in CPHN cells in CP, often in a lobular distribution, may indicate foci of attempted endocrine cell regeneration.
Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations
Trabert, Britton , Waterboer, Tim , Idahl, Annika , Brenner, Nicole , Brinton, Louise A. , Butt, Julia , Hartge, Patricia, Hufnagel, Katrin , Inturrisi, Federica , Lissowska, Jolanta , Mentzer, Alexander J. , Pepłońska, Beata , Wills, Gillian, Woodhall, Sarah C , Wentzensen, Nicolas , Trabert, B , Lissowska, Jolanta , Coburn, Sally B. , Sherman, Mark E. , Pawlita, Michael , Mentzer, Alexander J

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 4, 2018 | Volume: 111 | Issue: 2 | Pages: 129-136

10.1093/jnci/djy084 | PMID 29790947 Get It

Elevated LGI1‐IgG CSF index predicts worse neurological outcome
Gadoth, Avi , Ζεκερίδου, Αναστασία , Klein, Christopher J. , Thoreson, Colton J., Majed, Masoud , Dubey, Divyanshu , McKeon, Andrew , Jenkins, Sarah M. , Lennon, Vanda A. , Pittock, Sean J. , Zekeridou, Anastasia, Pittock, S J , Klein, Christopher J , McKeon, Andrew , Dubey, Divyanshu , Flanagan, Eoin P.

Mayo Clinic

Annals of Clinical and Translational Neurology | April 2, 2018 | Volume: 5 | Issue: 5 | Pages: 646-650

10.1002/acn3.561 | PMID 29761127 Get It

AbstractTo determine whether CSF leucine‐rich glioma‐inactivated 1(LGI1)‐IgG titer, index or IgG subclass has prognostic significance, we tested serum and CSF specimens collected concomitantly from 39 seropositive patients. LGI1‐IgG index was elevated (>1) in 21 patients (54%), suggesting intrathecal synthesis. Patients with worse outcome at last follow‐up (modified Rankin Scale >2) had significantly higher index (median 6.57 vs. 0.5, P = 0.048) compared to those with better outcome. Higher CSF LGI1‐IgG4 subclass‐specific titer and index correlated with worse outcome (P < 0.005 for both). These data suggest that evidence of intrathecal LGI1‐IgG synthesis may correlate with neuronal injury and warrant consideration of aggressive immunotherapy.
Adopted Individuals’ Views on the Utility and Value of Expanded Carrier Screening
Spencer, Sara , Ewing, Sarah, Calcagno, Kathryn, O’Neill, Suzanne C.

Mayo Clinic

Journal of Genetic Counseling | March 30, 2018 | Volume: 27 | Issue: 6 | Pages: 1341-1348

10.1007/s10897-018-0256-2 | PMID 29603037 Get It

AbstractAdoptees may not have family medical history and ethnicity information. Carrier screening assesses reproductive risk. Expanded carrier screening (ECS) screens for many genetic conditions regardless of a patient's knowledge of family history and ethnicity. This study aimed to better understand the opinions and attitudes of adopted individuals on the use of ECS in determining a patient's reproductive genetic risks. Specifically, the study assessed how adopted individuals feel that results of ECS may be useful to them and whether adoptees feel that meeting with a genetics professional in the process of undergoing ECS would be useful. Adult adoptees (N = 124) were recruited online. Their opinions on ECS were explored. The majority reported they had never been offered carrier screening (92%). The majority of adoptees wanted ECS (76%). Neither the amount of contact with biological relatives nor having medical knowledge about biological relatives was significantly associated with adoptees’ desire to pursue ECS. There was a significant positive correlation between adoptees of higher education levels and the amount they would pay for ECS (p = 0.004). The majority of participants (95%) indicated a genetics professional would be helpful when undergoing ECS. The findings suggest this population may want ECS and support from genetics healthcare professionals. Advocacy for genetic counseling and testing for adoptees appears justifiable.
Improved Self-Acceptance, Quality of Life, and Stress Level from Participation in a Worksite Yoga Foundations Program: A Pilot Study
Casey, Lori J., Rooy, Kimberly M. Van, Sutherland, Stephanie J., Jenkins, Sarah M. , Rosedahl, Jordan K., Wood, Nadia , Ebbert, Jon O. , Egginton, Jason S. , Sim, Leslie , Clark, Matthew M. , Van Rooy, Kimberly M, Wood, Nadia G, Rooy, Kimberly M. Van, López-Jiménez, Francisco , Wood, Nadia

Mayo Clinic

International Journal of Yoga Therapy | March 29, 2018 | Volume: 28 | Issue: 1 | Pages: 15-21

10.17761/2018-00013r2 | PMID 29596005 Get It

Abstract Yoga is increasing in popularity in the United States and across the globe. However, most yoga programs are provided outside the worksite; although many companies offer worksite wellness programs, at present there is limited documentation regarding the potential benefits of participating in a worksite yoga program. Therefore, the purpose of this project was to examine the potential effect of a worksite yoga program on self-acceptance, quality of life, and perceived stress. A prospective cohort pilot study that examined a structured worksite yoga program was designed and tailored to individuals new to yoga. The 8-week Yoga Foundations program was conducted at an academic medical center's worksite wellness center with 86 subjects. Outcome measures were the 36-item Self-Acceptance Scale; a six-item quality-of-life measure that assesses overall, social, mental, physical, emotional, and spiritual well-being; and the ten-item Perceived Stress Scale. Participants demonstrated significant improvement in their overall self-acceptance (p &lt; 0.001), quality of life (p &lt; 0.001), and perceived stress (p &lt; 0.001) levels. They also highly rated the yoga instructors and the weekly format of the program. Participation in a Yoga Foundations program was associated with improvements in self-acceptance, quality of life and stress levels in worksite wellness center members. Future studies should use randomized designs and examine other wellness domains to learn more about the potential benefits of worksite yoga programs.
P4472Targeted sequencing of 80 pharmacogenes reveals evidence for pleiotropic effects on serum LDL cholesterol levels
Nikroo, Nikta Dadkhah, Austin, Erin , Li, R. , Robertson, Peggy D., Stallings, Sarah , Larson, Eric B. , Linneman, James G., Jarvik, G.P., Crosslin, David R. , Schaid, Daniel J. , Network, eMERGE, Safarova, Maya , Andrade, Mariza de , Carrell, David , Bielinski, Suzette J. , Kullo, Iftikhar J. , Network, eMERGE

Mayo Clinic

European Heart Journal | March 29, 2018 | Volume: 38 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehx504.p4472 Get It